CD47 monoclonal antibodies and uses thereof
US12091467B2 · kind B2 · utility
0Cited by
46References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2020 |
| Grant date | Sep 17, 2024 |
| Priority date | — |
| Expiry date | Dec 29, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.